Director Henson gets 30,456 RSUs at Lisata Therapeutics (LSTA) stock

Rhea-AI Filing Summary

Lisata Therapeutics director Heidi Henson reported a new equity award. On January 9, 2026 she received 30,456 shares of common stock in the form of restricted stock units granted under Lisata’s 2018 Equity Incentive Compensation Plan at a grant price of $0 per share.

The restricted stock units are scheduled to vest on January 9, 2027, meaning the shares will become fully owned at that time if vesting conditions are met. After this grant, Henson beneficially owns 85,725 shares of Lisata common stock, which includes 30,456 unvested restricted stock units. The filing characterizes her ownership as direct.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENSON HEIDI

(Last) (First) (Middle)

C/O LISATA THERAPEUTICS, INC.

110 ALLEN ROAD, 2ND FLOOR

(Street)

BASKING RIDGE NJ 07920

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LISATA THERAPEUTICS, INC. [ LSTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		A		30,456(1)	A	$0	85,725(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027.

2. Includes 30,456 unvested restricted stock units.

Remarks:

	James Nisco, Attorney-in-fact for Heidi Henson	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lisata Therapeutics (LSTA) report for Heidi Henson?

The company reported that director Heidi Henson received 30,456 shares of common stock in the form of restricted stock units on January 9, 2026, at a grant price of $0 per share.

What type of equity award did Heidi Henson receive from Lisata Therapeutics (LSTA)?

Heidi Henson received 30,456 restricted stock units granted under Lisata Therapeutics’ 2018 Equity Incentive Compensation Plan, each representing a right to receive one share of common stock.

When do Heidi Henson’s restricted stock units at Lisata Therapeutics (LSTA) vest?

The 30,456 restricted stock units granted to Heidi Henson are scheduled to vest on January 9, 2027, according to the Form 4 footnote.

How many Lisata Therapeutics (LSTA) shares does Heidi Henson beneficially own after this transaction?

After the reported grant, Heidi Henson beneficially owns 85,725 shares of Lisata Therapeutics common stock, which includes 30,456 unvested restricted stock units.

Is Heidi Henson’s ownership in Lisata Therapeutics (LSTA) reported as direct or indirect?

The Form 4 indicates that Heidi Henson’s 85,725 shares of beneficial ownership, including the restricted stock units, are held as direct ownership.

What is the role of Heidi Henson at Lisata Therapeutics (LSTA)?

The Form 4 identifies Heidi Henson as a director of Lisata Therapeutics, with no officer title and not as a 10% owner.